Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists
This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.
- Trial name
- RAMPHA (NCT05600218)
- Testing
- No intervention - Observational study
- Where
- 10 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Costa del Sol
Lung Cancer, Lung Infection
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules.
- Conditions
- Lung Cancer, Lung Infection, COPD, Bronchitis
- Trial name
- NCT06528418
- Testing
- Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ChromX Health
Pulmonary Arterial Hypertension
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.
- Trial name
- NCT00323297
- Testing
- Bosentan, Sildenafil Citrate
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 105 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
StratosPHere (Non-interventional Study)
Pulmonary Arterial Hypertension is a progressive disease that has no cure. Patients die young and are limited in their daily activity. Current treatments only treat the symptoms of the disease rather than the underlying cause.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Hypertension, Respiratory Disease
- Trial name
- NCT05767918
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Papworth Hospital NHS Foundation Trust
Secondary Pulmonary Arterial Hypertension, Sickle Cell Disease
Pulmonary Hypertension in Patients With Sickle Cell Disease in Nigeria
This study will explore how people with sickle cell disease (SCD) develop a complication called pulmonary hypertension (PHTN), a serious disease in which blood pressure in the lungs is higher than normal.
- Conditions
- Secondary Pulmonary Arterial Hypertension, Sickle Cell Disease, Pulmonary Hypertension
- Trial name
- NCT00367523
- Where
- Nigeria
- Volunteers
- 308 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Systemic Sclerosis, Pulmonary; Hypertension
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients.
- Trial name
- NCT02981082
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Robert Lafyatis
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in patients with pulmonary arterial hypertension PAH, who live permanently…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, High Altitude, Echocardiography
- Trial name
- NCT07804524
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
- Trial name
- NCT00091715
- Testing
- bosentan
- Where
- 34 sites in United States, Australia and 12 more
- Volunteers
- 185 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension
Study Rationale:There is recent evidence that HIV protease inhibitors (HIV-PI) can improve pulmonary hemodynamics in experimental models of pulmonary arterial hypertension (PAH).
- Trial name
- NCT02023450
- Testing
- saquinavir and ritonavir
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Hypertension, Pulmonary
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension.
- Trial name
- NCT01824290
- Testing
- Tadalafil, ERA as specific PAH treatment
- Where
- 43 sites in United States, Austria and 12 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension
Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension
In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT05339386
- Testing
- Hyperpolarized Xe129
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Kansas Medical Center
Pulmonary Arterial Hypertension WHO Group I
Imaging Control Study, 3D Echo, MR and RHC.
The aim of the study is to intensify the follow up of patients with pulmonary arterial hypertension via modern imaging guided methods in due consideration of the possibilities of three-dimensional echocardiography in order to…
- Trial name
- PARIS (NCT02198456)
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Regina Steringer-Mascherbauer
Pulmonary Arterial Hypertension
Ventricular Reversed Remodeling After LTX in PAH Patients
The investigators will evaluate ventricular reversed remodelling after double lung transplantation (LTX) in patients with pulmonary arterial hypertension (PAH), measured with cardiac magnetic resonance imaging (MRI).
- Trial name
- PAH-LTX (NCT02391441)
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- University Medical Center Groningen
Pulmonary Arterial Hypertension
A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
Pulmonary arterial hypertension (PAH) is characterized by premature death mainly because of progressive and severe right ventricular failure.
- Trial name
- PADN-PAH (NCT02284737)
- Testing
- PADN, Sildenafil
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Interstitial Lung Disease, Comorbidities and Coexisting Conditions
Taiwan Interstitial Lung Disease Multi-center Investigation and Registry
The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease.
- Conditions
- Interstitial Lung Disease, Comorbidities and Coexisting Conditions, Pulmonary Arterial Hypertension, Treatment Adherence
- Trial name
- TAILI (NCT06476470)
- Where
- Taiwan
- Volunteers
- 10,000 people
- Sponsor
- Taichung Veterans General Hospital
Pulmonary Arterial Hypertension
Olaparib for PAH: a Pilot Study
The main OBJECTIVE of this proposal is to extend our preclinical findings on the role of DNA damage and poly(ADP-ribose) polymerases (PARP) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension (PAH)…
- Trial name
- OPTION-p (NCT03251872)
- Testing
- Olaparib
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Laval University
Pulmonary Arterial Hypertension
Effects of Physical Training on Vascular Function as a Therapeutic Target in Pulmonary Hypertension
The role of physical training in the treatment of pulmonary arterial hypertension (PAH) is controversial. The aim of the project is to evaluate the effect of physical training on markers of endothelial function and integrity and…
- Trial name
- NCT03550729
- Testing
- Endurance training
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Clinic of Barcelona
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
This is a four-part study of the safety, tolerability, and PK profile of sodium nitrite inhalation solution (AIR001) of ascending multiple doses (Part A) and of escalating doses with steady-state sildenafil (Part B) to healthy…
- Trial name
- NCT01409122
- Testing
- 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Aires Pharmaceuticals, Inc.
Pulmonary Artery Hypertension, Congenital Heart Disease
Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires
Background: A heart catheterization is a diagnostic heart procedure used to measure pressures and take pictures of the blood flow through the heart chambers.
- Conditions
- Pulmonary Artery Hypertension, Congenital Heart Disease, Structural Heart Disease
- Trial name
- NCT03152773
- Testing
- MRI Heart guidewire catheterization
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy…
- Trial name
- TripleTRE (NCT06317805)
- Testing
- Generic treprostinil sodium + Standard of Care (Double Oral), Standard of Care - Double Oral
- Where
- 28 sites in Argentina, Austria and 10 more
- Volunteers
- 110 people
- Sponsor
- AOP Orphan Pharmaceuticals AG